Beta Bionics (BBNX) Cash & Current Investments (2023 - 2026)

Beta Bionics has disclosed Cash & Current Investments across 4 years of filings, most recently posting $30.3 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $30.3 million, down 86.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (down 86.91% YoY), and the FY2025 annual result was $219.1 million, up 111.56% from the prior year.
• Cash & Current Investments came in at $30.3 million for Q1 2026 at Beta Bionics, down from $219.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $249.7 million in Q2 2025 to a low of $13.0 million in Q2 2024.
• The 4-year median for Cash & Current Investments is $100.2 million (2023), against an average of $121.2 million.
• Across the five-year window, Cash & Current Investments soared 1816.65% in 2025 and slumped 86.91% in 2026, its largest moves.
• Beta Bionics' Cash & Current Investments stood at $96.7 million in 2023, then gained by 7.06% to $103.6 million in 2024, then surged by 111.56% to $219.1 million in 2025, then tumbled by 86.17% to $30.3 million in 2026.
• The last three Cash & Current Investments figures came in at $30.3 million (Q1 2026), $219.1 million (Q4 2025), and $228.7 million (Q3 2025), per Business Quant data.